Walker B R, Erickson A L, Prost J F, Rochat C, Burke T J
J Cardiovasc Pharmacol. 1985 Nov-Dec;7(6):1193-7. doi: 10.1097/00005344-198511000-00029.
The cardiac and renal hemodynamic effects of SE2395, a beta-blocking agent, were examined after intravenous administration (50 micrograms/kg) in normotensive conscious dogs. Beta-blocking action of SE2395 was evidenced by a reduction in heart rate and cardiac output without change in the mean arterial pressure. An increase in glomerular filtration rate (inulin clearance) and a slight enhancement in effective renal plasma flow (para-aminohippurate clearance) were observed without attendant decreases in plasma renin activity. An increase in urinary sodium excretion was also observed; urinary prostaglandin E2 excretion was, however, unchanged. We conclude that at effective beta-blocking dosage SE2395 does not induce any detrimental effect on renal function in conscious dogs.
在正常血压的清醒犬静脉注射(50微克/千克)β受体阻滞剂SE2395后,检测了其对心脏和肾脏血流动力学的影响。SE2395的β受体阻滞作用表现为心率和心输出量降低,而平均动脉压无变化。观察到肾小球滤过率(菊粉清除率)增加,有效肾血浆流量(对氨基马尿酸清除率)略有增强,同时血浆肾素活性未见降低。尿钠排泄也增加;然而,尿前列腺素E2排泄未发生变化。我们得出结论,在有效的β受体阻滞剂量下,SE2395对清醒犬的肾功能不会产生任何有害影响。